Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Authors
Keywords
PI3K, mTOR, Phase I, Small molecule
Journal
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 3, Pages 510-517
Publisher
Springer Nature
Online
2014-01-06
DOI
10.1007/s10637-013-0062-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
- (2015) Oncotarget
- Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data.
- (2014) JL Canon et al. CANCER RESEARCH
- PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
- (2013) Seth A. Wander et al. BREAST CANCER RESEARCH AND TREATMENT
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
- (2013) Carolyn D. Britten CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
- (2013) A. Herzog et al. CLINICAL CANCER RESEARCH
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
- (2012) Brett H. Simmons et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology.
- (2012) R. Millham et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
- (2011) R. Mallon et al. CLINICAL CANCER RESEARCH
- In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
- (2011) K. M. Kinross et al. MOLECULAR CANCER THERAPEUTICS
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
- (2011) Shin Ogita et al. Targeted Oncology
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy
- (2009) N. T. Ihle et al. MOLECULAR CANCER THERAPEUTICS
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Mammalian target of rapamycin as a therapeutic target in oncology
- (2008) Robert T Abraham et al. EXPERT OPINION ON THERAPEUTIC TARGETS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now